NewAmsterdam Pharma Company NV - Warrants (15/11/2027)
NAMSW
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.54B
Close$
$2.97
81.4% downside
Current Fair Value
81.4% downsideOvervalued by 81.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.54 Billion |
|---|---|
| Enterprise Value | $3.12 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.75 |
| Beta | 0.11 |
| Outstanding Shares | 123,370,232 |
Return
| Return on Equity | -41.10% |
|---|---|
| Return on Assets | -36.84% |
| Return on Invested Capital | -40.57% |
Valuation & Multiples
| P/E Ratio | -11.88 |
|---|---|
| PEG | -4.41 |
| Price to Sales | - |
| Price to Book Ratio | 3.2 |
| Enterprise Value to Revenue | 437.57 |
| Enterprise Value to EBIT | -12.16 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.50
Average shareholder expectationRevenue Estimate
$7.54 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data